ACKNOWLEDGEMENTS
Shane Winzar, Denese
WHITMORE
The authors would like to acknowledge Michael Whitmore, former head of process development, Exopharm; the ARCBS Lifeblood (Denese Marks, Shane Winzar, Augustin Raj) for providing PLTs and technical input. Gerard Tarulli (University of Melbourne, Melbourne, Australia) for assistance with confocal microscopy; The Bio21 Mass Spectrometry and Proteomics Facility and Advanced Microscope Facility (Melbourne, Australia) for mass spectrometry and electron microscopy; Cameron Kos, Lina Mariana and Thomas Loudovaris (St Vincent's Institute, Melbourne, Australia) for their assistance in the operation of the isolator facility during the clinical trial; Avania (Collingwood, Victoria, Australia) for clinical trial monitoring and data review; Stephen Hall (Emeritus Research, Camberwell, Victoria, Australia), clinical trial principal investigator.